Partnering
Xeris is developing its pipeline both through internal clinical development and external partnerships to advance the commercial potential of its products globally.
Partnering
Xeris is interested in establishing a portfolio of strategic collaborations with key partners who wish to codevelop products using Xeris’ platform technologies (XeriSol™ and XeriJect™).
Currently, Xeris is working on a number of formulation feasibility programs in the areas of peptides, vaccines, and monoclonal antibodies.
We welcome the opportunity to discuss areas of potential common interest from which to build value for both parties.
To discuss partnering opportunities, please contact us.
You have chosen a link to an external site.
By clicking "ok", a new window will open.
Do you wish to continue?
OK No Thanks!Not opening? Check to see you have pop-ups enabled or copy link below in a new window.
Xeris Biopharma is excited to announce approval for a new product, furthering our commitment to improving more patient's lives. Read More
Product Pipeline
Xeris has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms.
Find out more
Approved Products
Gvoke® (glucagon injection)
Fact Sheet
Keveyis® (dichlorphenamide)
Fact Sheet
Recorlev® (levoketoconazole)
Fact Sheet